Could tapping into 401k investment be a gamechanger for Houston startup funding? Photo via Getty Images

With fossil fuels facing an uncertain future, Houston is wisely pushing to further develop its innovation economy with initiatives like Houston Exponential and Rice Management Company's Ion, as well as the No. 1 ranked entrepreneurship programs at the University of Houston (undergraduate) and Rice (graduate).

Venture capital is both the critical fuel and limiting factor to expanding Houston's innovation ecosystem, but the vast majority of venture capital in this country is focused outside of Houston in places like Silicon Valley and Austin. How can we increase the local pool of venture capital focused on Houston?

A recent federal guidance provides the answer with a new option for adding dramatically to Houston's venture capital resources. On June 3rd 2020, the Department of Labor issued an information letter allowing 401k funds to invest in private equity, including venture capital. Houston has hundreds of thousands of employees contributing to 401k retirement plans, including those working at our 41 Fortune 1000 companies as well as other major employers like the Texas Medical Center hospitals. If even a small fraction of their savings could be channeled into Houston-focused venture capital funds (or funds of funds like the HX Venture Fund), it could add hundreds of millions of dollars to Houston's startup ecosystem.

How would this work? While federal guidance does not allow direct private equity investments in 401k plans, it does allow private equity to be part of the mix in target date, target risk, or balanced funds offered. Imagine the creation of a "Houston Balanced Fund" focused on a portfolio of equities and bonds from Houston companies, local government bonds, and a 15 percent allocation to Houston-focused venture capital (the maximum allowed for illiquid assets). The fund would be a bet on a prosperous long-term future for Houston — something I think many Houstonians would enthusiastically add to their retirement portfolios. Once created, it could be added to the investment options in 401k employer plans all over the city.

As an example of the power of this model: if 100,000 employees — only 3 percent of 3 million jobs in the Houston metro — invested just $10,000 of their 401k portfolios into a Houston Balanced Fund with 15 percent allocated to venture capital, it would inject an additional $150 million dollars into the local venture capital pool to spur new innovations and companies that can be the future of Houston's economy — a 20 percent increase to the $715 million of venture capital invested in Houston in 2020. This new venture capital could be leveraged even more by focusing it on early-stage Houston startups that might have trouble attracting the attention of national VC firms. As they mature to Series B rounds and beyond, they should have no trouble bringing in capital from outside the region.

This is an opportunity for Houston to do something no other city has done — to be innovative with not just new ventures and technologies, but with how they're financed. We can be proactive pioneers fueling Houston's 21st-century innovation ecosystem.

------

Tory Gattis writes the Houston Strategies blog and is a Founding Senior Fellow with the Urban Reform Institute – A Center for Opportunity Urbanism.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”